Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q2 2023 Results Conference Call August 9, 2023 4:30 PM ET
Company Participants
Andrea Flynn - VP & Head, IR
Bruce Cozadd - Chairman and Chief Executive Officer
Renee Gala - Executive Vice President and Chief Financial Officer
Dan Swisher - President and Chief Operating Officer
Rob Iannone - Executive Vice President, Global Head of R&D
Kim Sablich - Executive Vice President and General Manager of United States
Conference Call Participants
Jason Gerberry - Bank of America
Joseph Thome - TD Cowen
Marc Goodman - Leerink Partners
Akash Tewari - Jefferies
David Amsellem - Piper Sandler
Ami Fadia - Needham
Gregory Renza - RBC Capital Markets
Annabel Samimy - Stifel
Jeff Hung - Morgan Stanley
Mohit Bansal - Wells Fargo
Joon Lee - Truist Securities
Charles Duncan - Cantor Fitzgerald
Operator
Good afternoon and thank you for attending the Jazz Pharmaceuticals Second Quarter 2023 Financial Results Call. My name is Elissa, and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end.
I would now like to pass the call over to the Jazz Pharmaceuticals team. You may proceed.
Andrea Flynn
Thank you, operator, and good afternoon, everyone. Today, Jazz Pharmaceuticals supported its second quarter 2023 financial results. The slide presentation accompanying this webcast is available on the Investors section of our website. Investors may also refer to the press release we issued earlier today, which is also posted to our website.
On the call today are Bruce Cozadd, Chairman and Chief Executive Officer; Renee Gala, Executive Vice President and Chief Financial Officer; Dan Swisher, President and Chief Operating Officer; and Rob Iannone, Executive Vice President, Global Head of R&D; Kim Sablich, Executive Vice President and General Manager of United States, will join the team for Q&A.
On Slide 2, I'd like to remind you that today's webcast includes forward-looking statements, such as those related to our future financial and operating results, growth potential and anticipated development and commercialization milestones and goals which involve risks and uncertainties that could cause actual events, performance and results to differ materially from those contained in these forward-looking statements.
We encourage you to review the statements contained in today's press release, in our slide deck and in our latest SEC disclosure documents, which identify certain factors that may cause the Company's actual events, performance and results to differ materially from those contained in the forward-looking statements made on today's webcast. We undertake no duty or obligation to update our forward-looking statements.